Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)

This study has been completed.
Information provided by (Responsible Party):
Alexion Pharma GmbH Identifier:
First received: August 27, 2008
Last updated: May 27, 2014
Last verified: May 2014

August 27, 2008
May 27, 2014
September 2008
May 2010   (final data collection date for primary outcome measure)
  • Number of Patients Showing Radiographic Response After 24 Weeks of Treatment [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]
    A 7-point RGI-C (Radiographic Global Impression of Change) score was used to rate change in rickets severity. Scores ranged from -3 (severe worsening of rickets) to +3 (complete healing of rickets). Only those patients with a minimum score of +2 indicating substantial healing of rickets) were considered "responders". Three pediatric radiologists not affiliated with the conduct of the study performed the ratings.
  • Number of SAEs (Serious Adverse Events) for All Treated Patients [ Time Frame: 24 weeks ] [ Designated as safety issue: Yes ]
    The number and description of all SAEs experienced by treated patients were reported and classified according to the relationship to treatment
  • To assess the efficacy of ENB-0040 in treating the skeletal manifestations of infantile HPP [ Time Frame: Upon Study Completion (6 months - 1 year) ] [ Designated as safety issue: No ]
  • To determine the safety and tolerability of ENB-0040 given intravenously (IV) in a single dose and subcutaneously (SC) in repeat doses [ Time Frame: Throughout the course of the investigation and upon study completion (6 months - 1 year) ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00744042 on Archive Site
Not Provided
  • To assess the pharmacokinetics (PK) of ENB-0040 given IV and SC [ Time Frame: Upon Study Completion (6 months - 1 year) ] [ Designated as safety issue: No ]
  • To assess the bioavailability of SC ENB-0040 [ Time Frame: Upon Study Completion (6 months - 1 year) ] [ Designated as safety issue: No ]
Not Provided
Not Provided
Safety and Efficacy Study of Asfotase Alfa in Severely Affected Infants With Hypophosphatasia (HPP)
A Multicenter, Open-Label Study of the Safety, Tolerability and Pharmacology of ENB-0040 (Enobia's Human Recombinant Tissue Non-specific Alkaline Phosphatase Fusion Protein) in up to 10 Severely Affected Patients With for the Treatment of Severely Affected Patients With Infantile Hypophosphatasia (HPP)

This clinical trial studies the safety and efficacy of asfotase alfa in infants and young children with infantile onset HPP.

Hypophosphatasia (HPP) is a life-threatening, genetic, and ultra-rare metabolic disease characterized by defective bone mineralization and impaired phosphate and calcium regulation that can lead to progressive damage to multiple vital organs, including destruction and deformity of bones, profound muscle weakness, seizures, impaired renal function, and respiratory failure. There are no approved disease-modifying treatments for patients with this disease. There is also limited data available on the natural course of this disease over time, particularly in patients with the juvenile-onset form.

Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Hypophosphatasia (HPP)
Biological: asfotase alfa
Other Names:
  • Asfotase Alfa was formerly referred to as ENB-0040
  • Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein
asfotase alfa
Intervention: Biological: asfotase alfa

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
May 2010
May 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Legal guardian(s) must provide informed consent prior to any study procedures
  • Documented diagnosis of severe HPP as indicated by:

    • Total serum alkaline phosphatase at least 3 standard deviations (SD) below the mean for age
    • Plasma pyridoxal 5'-phosphate (PLP) at least 4 times the upper limit of normal
    • Radiographic evidence of HPP (hypophosphatasia), characterized by:

      • Flared and frayed metaphyses
      • Severe, generalized osteopenia
      • Widened growth plates
    • One or more HPP-related findings:

      • History or presence of:

        • Non-traumatic post-natal fracture
        • Delayed fracture healing
      • History of elevated serum calcium
      • Functional craniosynostosis with decreased head circumference growth
      • Nephrocalcinosis
      • Respiratory compromise
    • Rachitic chest deformity and/or vitamin B6 dependent seizures
    • Failure to thrive
  • Onset of symptoms prior to 6 months of age
  • Age ≤ 36 months
  • Otherwise medically stable (patient may be on ventilatory support)
  • Legal guardian(s) must be willing to comply with the study

Exclusion Criteria:

  • History of sensitivity to any of the constituents of the study drug
  • Current or prior clinically significant cardiovascular, endocrinologic, hematologic, hepatic, immunologic, metabolic, infectious, urologic, pulmonary, neurologic, dermatologic, renal condition and/or other major disease which, in the opinion of the investigator, precludes study participation
  • Treatment with an investigational drug within 1 month prior to the start of study drug administration
  • Current enrollment in any other study involving an investigational new drug, device or treatment for HPP (e.g., bone marrow transplantation)
  • Low serum calcium, phosphate or 25(OH) vitamin D
  • Current evidence of a treatable form of rickets
  • Prior treatment with bisphosphonate
up to 36 Months
Contact information is only displayed when the study is recruiting subjects
United States,   Canada,   United Arab Emirates,   United Kingdom
Alexion Pharma GmbH
Alexion Pharma GmbH
Not Provided
Not Provided
Alexion Pharma GmbH
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP